Complexities of oestradiol pharmacology in pulmonary arterial hypertension

European Respiratory Journal

Volumn 41, Issue 6, 2013, Pages 1465-1466

  Tofovic, Stevan P ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; CYCLOOXYGENASE 2; ESTRADIOL; NITRIC OXIDE; PROSTACYCLIN; ENDOTHELIN 1;

DOWN REGULATION; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; ESTRADIOL BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; GENDER; HORMONE ACTION; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEX DIFFERENCE; UPREGULATION; ANIMAL; FEMALE; HYPERTENSION, PULMONARY; METABOLISM;

ANIMALS; ENDOTHELIN-1; EPOPROSTENOL; ESTRADIOL; FEMALE; HYPERTENSION, PULMONARY; NITRIC OXIDE;

EID: 84878802566     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00164912     Document Type: Letter

References (8)

1. Yuan P, Wu WH, Gao L, et al. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, PGI2 and ET-1 pathways. Eur Respir J 2012; 41: 1116-1125.
2. Tofovic SP. Estrogens and development of pulmonary hypertension - interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010; 56: 696-708.
3. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
4. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
5. Escribano-Subias P, Blanco I, Lopez-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012; 40: 596-603.
6. Barchiesi F, Jackson EK, Fingerle J, et al. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 2006; 99: 266-74. (Pubitemid 44174934)
7. Tofovic SP, Rafikova O, Jackson EK, et al. Estrogens exacerbates development of occlusive pulmonary arterial hypertension and formation of plexiform lesions. Am J Respir Crit Care Med 2012; 185: A6803.
8. Roberts KE, Fallon MB, Krowka MJ, et al. Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835-842.